Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1223-1228

  Schulze, R ^a,d   Schulze, M ^a   Wischnik, A ^b   Ehnle, S ^a   Doukas, K ^c   Behr, W ^c   Ehret, W ^c   Schlimok, G ^a  

^a 2 Medizinische Klinik   (Germany)

^b Frauenklinik ^*

^c Inst für Laboratoriumsmedizin   (Germany)

^d KLINIKUM AUGSBURG   (Germany)

Author keywords

Bone marrow; Breast cancer; Peripheral blood stem cell transplantation; Tumor cells

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOKERATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER SURVIVAL; CELL SEPARATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; TUMOR CELL;

EID: 0030760349     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700817     Document Type: Article

References (46)

1. Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science 1991; 254: 1131-1137.
2. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
3. Peters WP, Berry D, Vredenburgh JJ et al. Five-year follow-up of high-dose combinating alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (DUKE/CALGB 8782). Proc Am Soc Clin Oncol 1995; 14: A933 (Abstr.).
4. Gianni AM, Siena S, Bregni M et al. 5-year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes. Proc Am Soc Clin Oncol 1995; 14: A61 (Abstr.).
5. Brugger W, Brass K, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
6. Moss TJ, Cairo MS, Bostrom B et al. Using bone marrow (BM) immunocytochemical (ICC) analysis to determine optimal timing of peripheral blood stem cell (PBSC) harvest for patients with breast cancer and neuroblastoma. Blood 1994; 84(Suppl. 1): 1401 (Abstr.).
7. Sharp JC, Kessinger A, Mann S et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Clon 1992; 10 (Suppl. 1): 92-94.
8. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
9. Weaver CH, Hazelton B, Ross AA, Schwartzberg L. The incidence of tumor cell contamination in peripheral blood progenitor cell (PBPC) collections in patients with breast cancer. Blood 1994; 84 (Suppl. 1): 1389a (Abstr.).
10. Pantel K, Schlimok G, Angstwurm M et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-173.
11. Schlimok G, Funke I, Holzmann B et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labelling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672-8676.
12. Schlimok G, Riethmüller G. Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Sem Canc Biol 1990; 1: 207-215.
13. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
14. Debus E, Moll R, Franke WW. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 1984; 114: 121-130.
15. Debus E, Weber K, Osborne M. Monoclonal cytokeratin antibodies that distinguish simple from stratified squamous epithelia. EMBO J 1982; 1: 1641-1647.
16. Karsten U, Papsdorf G, Roloff G. Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol 1985; 21: 733-740.
17. Kasper M, Stosiek P, Typlt H et al. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 1987; 23: 137-147.
18. Karsten U, Widmaier R, Kunde D. Monoclonal antibodies against antigens of the human mammary carcinoma cell line MCF-7. Arch Geschwulstforsch 1983; 53: 529-536.
19. Pantel K, Braun S, Passlick B, Schlimok G. Minimal residual epithelial cancer. Prog Histochem Cytochem 1996; 30: 1-62.
20. Schlimok G, Riethmüller G. Monoclonal antibodies in the therapy of minimally residual solid tumors. Onkologie 1995; 18: 403-408.
21. Schlimok G, Lindemann F, Holzmann K et al. Prognostic significance of tumor cells detected in bone marrow of breast cancer patients: a multivariate analysis. Onkologie 1994; 17 (Suppl. 2): 128 (Abstr.).
22. Diel IJ, Kaufmann M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10: 1534-1539.
23. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
24. Mansi JL, Berger U, Easton D et al. Micromestastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 1987; 295: 1093-1096.
25. Mansi JL, Easton D, Berger U et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6-years' follow-up. Eur J Cancer 1991; 27: 1552-1555.
26. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225-232.
27. Schlimok G, Pantel K, Riethmüller G. Autologous stem cell transplantation in breast cancer: does stem cell mobilization treatment mobilize tumor cells? Blood 1993; 82 (Suppl. 1): 653a (Abstr.).
28. Schulze R, Schulze M, Wischnik A et al. Tumor cell contamination of peripheral blood stem cell transplants (PBSCT) and/or bone marrow (BM) in high risk breast cancer patients (n ≥ 10). Blood 1995; 82 (Suppl. 1): 234a (Abstr.).
29. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation of B-cell lymphomas. New Engl J Med 1991; 325: 1525-1533.
30. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
31. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994; 8: 25-31.
32. Sharp JG. Micrometastases and transplantation. J Hematother 1996; 5: 519-524.
33. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
34. Müller P, Weckermann D, Riethmüller G, Schlimok G. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 1996; 88: 8-16.
35. Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 4: 725-729.
36. Datta YH, Adams PT, Drobyski WR et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 3: 475-482.
37. Pantel K, Detection of minimal disease in patients with solid tumors. J Hematother 1996; 5: 359-367.
38. Krismann M, Todt B, Schröder J et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-2775.
39. Schoenfeld A, Luqmani Y, Smith D et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994; 54: 2986-2990.
40. Zippelius A, Honold G, Küfer P et al. Potential and limitations of RT-PCR for detection of isolated carcinoma cells in bone marrow. Exp Hematol 1995; 23: 763 (Abstr.).
41. Zippelius A, Kufer P, Honold G et al. Limitations of reverse transcriptase-polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. Blood 1996; 88 (Suppl. 1): 2431 (Abstr.).
42. Corradini P, Cinque F, Astolfi M et al. Detection of minimal residual disease in patients with breast cancer: a novel nested-PCR assay using maspin gene. Blood 1996; 88 (Suppl. 1): 972 (Abstr.).
43. Jung K, Henke W, Lein M et al. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996; 78: 2445-2447.
44. Ross AA, Cooper BW, Warner NE et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
45. Ross AA, Layton TJ, Ostrander AB et al. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother 1996; 5: 549-552.
46. Ybanez J, Lazarus HM, Ross AA et al. Impact of occult tumor reinfusion on outcome after high-dose chemotherapy in patients with advanced breast cancer. Blood 1995; 86: 386a (Abstr.).